



Meeting the Moment



Navigating a year like no other

Between the global COVID-19 pandemic and a national awakening on racism from city streets to Wall Street boardrooms, 2020 was a year of extraordinary circumstances. We incorporated these shifts into our work, elevating the distinctly racialized dimensions of who gets hurt most in a medicines system designed to maximize revenue, highlighting racial disparities in COVID vaccine distribution, and showing how systems improvements could better prepare us for an equitable response to the next pandemic.

Our Impact



52 media hits on I-MAK’s work, including 29 COVID-related stories



Connected with 2,000 people through 22 speaking engagements



Drew high-level media attention to racial inequities in pandemic response

Creating the tools to win the fight

We took on 2020 using I-MAK’s model of research, education, and partnerships. We created a comprehensive data page used by the House Oversight Committee to investigate the pharmaceutical industry. Our data was cited in Congressional testimony, as well as three staff reports. We also exposed an exploitative patent strategy by AbbVie to extend its monopoly on Imbruvica by nine years, during which time Americans will spend \$41 billion on the bestselling cancer drug.

Founders’ Letter

From a devastating pandemic that’s taken the lives of more than two million people worldwide to the long overdue confrontation of America’s racial injustices both systemic and personal – 2020 was a year of seismic change.

At I-MAK, it was also a year of tremendous opportunity. The work we’ve done over the past two decades led us to be uniquely prepared to react and respond to the moment.

We called out “vaccine nationalism” that will cost twice as many lives globally, while also identifying ways to build a more just drug development system. We wove the two biggest issues facing the country – COVID-19 and racial justice – into a cohesive narrative around the racial disparities within the vaccine distribution plan, and the ways in which we can improve and change our systems to better prepare us for an equitable response to the next pandemic.

Through it all, we worked to prioritize our team’s well being, meet family needs, and manage the unyielding stress of navigating a world where the only certainty seemed to be uncertainty.

We’re not yet on the other side of it, but we can see the light at the end of this long and winding tunnel. 2020 was the year of exposing the problems within our healthcare systems, and 2021 is the year to offer solutions on how we finally achieve a more just and equitable medicine system for all. We hope you’ll join us.



Priti Krishtel & Tahir Amin
Co-Founders / Co-Executive Directors

Finances

OPERATING SUPPORT & REVENUE SOURCES	
Contributions and Grants	\$726,912
Program Service Revenue	\$226,699
Total operating support & revenue . .	\$953,611

PROGRAM & OPERATING EXPENSES	
1 Program Services	\$668,096 (77%)
2 General and Administrative . .	\$136,542 (16%)
3 Development and Fundraising .	\$58,782 (7%)
Total operating expenses	\$863,420

Total assets	\$1,400,880
Total liabilities	\$147,246

Net assets or fund balances	\$1,253,634
--	--------------------

We must solve the drug patent problem

Join us at i-mak.org